Título : |
Differential characteristics in drug-induced autoimmune hepatitis |
Tipo de documento : |
documento electrónico |
Autores : |
Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, |
Fecha de publicación : |
2018 |
Títulos uniformes : |
JGH Open
|
Idioma : |
Inglés (eng) |
Palabras clave : |
Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis |
Resumen : |
Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P |
Mención de responsabilidad : |
Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez |
Referencia : |
JGH Open. 2018 May 24;2(3):97-104. |
DOI (Digital Object Identifier) : |
10.1002/jgh3.12054 |
PMID : |
30483571 |
Derechos de uso : |
CC BY-NC |
En línea : |
https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 |
Differential characteristics in drug-induced autoimmune hepatitis [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, . - 2018. Obra : JGH OpenIdioma : Inglés ( eng) Palabras clave : |
Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis |
Resumen : |
Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P |
Mención de responsabilidad : |
Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez |
Referencia : |
JGH Open. 2018 May 24;2(3):97-104. |
DOI (Digital Object Identifier) : |
10.1002/jgh3.12054 |
PMID : |
30483571 |
Derechos de uso : |
CC BY-NC |
En línea : |
https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 |
| |